Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet

Volumn 386, Issue 9999, 2015, Pages 1137-1146

  McInnes, Iain B ^a   Mease, Philip J ^b   Kirkham, Bruce ^c   Kavanaugh, Arthur ^d   Ritchlin, Christopher T ^e   Rahman, Proton ^f   Van Der Heijde, Désirée ^g   Landewé, Robert ^h   Conaghan, Philip G ⁱ   Gottlieb, Alice B ^j   Richards, Hanno ^k   Pricop, Luminita ^k   Ligozio, Gregory ^k   Patekar, Manmath ^l   Mpofu, Shephard ^k  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d Center for the Future of Surgery   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

^f MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h Sittard Geleen Heerlen   (Netherlands)

ⁱ UNIVERSITY OF LEEDS   (United Kingdom)

^j TUFTS MEDICAL CENTER   (United States)

^k NOVARTIS PHARMA AG   (Switzerland)

^l Novartis Healthcare Private Limited   (India)

more..

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PLACEBO; SECUKINUMAB; ANTIRHEUMATIC AGENT; INTERLEUKIN 17; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; ASIA; AUSTRALIA; BLOODY DIARRHEA; CANADA; CANDIDIASIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANDIDIASIS; EUROPE; FEMALE; HEADACHE; HEART INFARCTION; HEMATURIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; SQUAMOUS CELL CARCINOMA; THRUSH; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VOMITING; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84942198180     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)61134-5     Document Type: Article

References (26)

1. D Gladman, C Antoni, P Mease, D Clegg, P Nash Psoriatic arthritis: epidemiology, clinical features, course, and outcome Ann Rheum Dis 64 2005 ii14 ii17
2. CF Rosen, F Mussani, V Chandran, L Eder, A Thavaneswaran, D Gladman Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone Rheumatology 51 2012 571 576
3. PJ Mease, AJ Kivitz, FX Burch et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression Arthritis Rheum 50 2004 2264 2272
4. C Antoni, GG Krueger, K de Vlam et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial Ann Rheum Dis 64 2005 1150 1157
5. PJ Mease, DD Gladman, CT Ritchlin et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a doubleblind, randomized, placebo-controlled trial Arthritis Rheum 52 2005 3279 3289
6. A Kavanaugh, I McInnes, P Mease et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study Arthritis Rheum 60 2009 976 986
7. PJ Mease, R Fleischmann, AA Deodhar et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) Ann Rheum Dis 73 2014 48 55
8. IB McInnes, A Kavanaugh, AB Gottlieb on behalf of the PSUMMIT 1 Study Group Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial Lancet 382 2013 780 789
9. C Ritchlin, P Rahman, A Kavanaugh et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial Ann Rheum Dis 73 2014 990 999
10. A Kavanaugh, PJ Mease, JJ Gomez-Reino et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor Ann Rheum Dis 73 2014 1020 1026
11. W O'Connor Jr, L Zenewicz, R Flavell The dual nature of TH17 cells: shifting the focus to function Nat Immunol 11 2010 471 476
12. BW Kirkham, A Kavanaugh, K Reich Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis Immunology 141 2013 133 142
13. C Jandus, G Bioley, J-P Rivals et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides Arthritis Rheum 58 2008 2307 2317
14. SP Raychaudhuri, SK Raychaudhuri, M Genovese IL-17 receptor and its functional significance in psoriatic arthritis Mol Cell Biochem 359 2012 419 429
15. B Menon, NJ Gullick, GJ Walter et al. IL-17+CD8+ T-cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression Arthritis Rheumatol 66 2014 1272 1281
16. O FitzGerald, R Winchester Emerging evidence for critical involvement of the interleukin-17 pathway in both psoriasis and psoriatic arthritis Arthritis Rheumatol 66 2014 1077 1080
17. RG Langley, BE Elewski, M Lebwohl et al. Secukinumab in plaque psoriasis: results of two phase three trials N Engl J Med 371 2014 326 338
18. PJ Mease, IB McInnes, B Kirkham et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study Arthritis Rheumatol 66 suppl 2014 S423 (abstr 923).
19. U Klein, E Liang, B Vogel, F Kolbinger, G Bruin, P Lloyd Immunogenicity of the anti-IL-17A antibody secukinumab in healthy subjects and patients J Invest Dermatol 133 suppl 1 2013 S172
20. DT Felson, JJ Anderson, M Boers et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis Arthritis Rheumatol 38 1995 727 735
21. S Weisman, CR Pollack, RW Gottschalk Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis J Dermatolog Treat 14 2003 158 165
22. G Wells, JC Becker, J Teng et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate Ann Rheum Dis 68 2009 954 960
23. V Strand, JA Singh Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials Am J Manag Care 14 2008 234 254
24. JF Fries, P Spitz, RG Kraines et al. Measurement of patient outcome in arthritis Arthritis Rheum 23 1980 137 145
25. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, June 2010 (available from http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5×7.pdf) (accessed May 14, 2015).
26. SL Gaffen, N Hernández-Santos, AC Peterson IL-17 signaling in host defense against Candida albicans Immunol Res 50 2011 181 187